Pharmaceutical

Search documents
X @Bloomberg
Bloomberg· 2025-10-10 16:58
AstraZeneca is expected to announce a deal with Trump to slash drug prices, people familiar with the plans said, making it the second pharmaceutical company to strike an agreement to advance one of the president's key health priorities https://t.co/TJppQUDFqI ...
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)
Seeking Alpha· 2025-10-07 14:38
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
Josh Brown's 'Best Stocks in the Market': Veeva Systems
CNBC Television· 2025-10-03 18:00
All right, best stocks in the market from Josh Brown. The spotlight today is on Viva. Vev on the list since May 29th of 2025.Tell me why. >> This might be like the only time this stock has ever been mentioned on on the network. Nobody nobody talks about it, but it >> could be the last time.It's >> it's this incredible company, Scott, and it literally is demanding that we pay attention to it based on um its performance. So, the stock broke out in May. It has since been consolidating just below um those 52- w ...
Eli Lilly in negotiations with Trump administration for the next pharma deal
CNBC Television· 2025-09-30 19:12
Well, I got some breaking news out of the White House, which means we're going to go to Aean Jabvers. Aean, Brian, uh, Eli Liy is the company that is in negotiations with the White House for a pharma deal similar to the one uh that Fizer struck earlier today that confirmed by the White House to me just within the past couple of moments. You can see uh Lily shares there have been moving throughout the day.That's because the president mentioned the company in the Fizer event. He said how terrific Eli Liy has ...
Pfizer CEO: 'The big winner of this deal clearly will be the American patient'
CNBC Television· 2025-09-30 18:00
The big winner of this deal clearly will be the American Pac. There is no doubt about it. They are the ones that will see significant impact in their ability to buy medicines.But I would argue that uh it is not the only winner. I think who else is a winner here. It is American innovation and American economy.In our industry, we had two major overhangs that have substantially reduced our valuations and create concerns for us in our ability to invest. We are addressing both of them right now and I will speak ...
X @Bloomberg
Bloomberg· 2025-09-29 12:58
The pharmaceutical industry’s US lobbying organization announced a new website on Monday to connect patients with companies selling discounted medicines online https://t.co/GH7Rr3W36L ...
Vertex Pharmaceuticals' Market Outlook and Challenges
Financial Modeling Prep· 2025-09-26 16:04
Stephens initiated coverage on NASDAQ:VERX with an "Overweight" rating, signaling a positive future outlook despite recent setbacks.Vertex faces significant challenges due to trial failures in its drug pipeline, notably in acute pain, diabetes, and neuropathic pain treatments.Despite these hurdles, strong sales from cystic fibrosis (CF) therapies and potential from new product launches suggest room for future growth.Vertex Pharmaceuticals, trading under the symbol NASDAQ:VERX, is a prominent player in the b ...
5 Things To Know: September 26, 2025
CNBC Television· 2025-09-26 11:16
Five things to know ahead of today's opening bell. President Trump threatening the pharmaceutical industry with 100% tariffs unless drug companies manufacture or at least start to build manufacturing plants in the United States. The president also saying that he plans to slap a 25% tariff on imported heavy trucks starting October 1st.Separately, President Trump said yesterday he hopes to take some of the money raised by his tariffs and give it to US farmers. Retaliation to President Trump's tariffs have red ...
The Dark Side of Fast-Tracked Cancer Drugs | Exclusive Preview
Bloomberg Originals· 2025-09-24 21:00
Drug Approval & Efficacy - Half (50%) of approved cancer drugs lack proof of extending survival for approved uses [1] - The pharmaceutical industry's primary motive is generating profits for shareholders [1] - Financial pressures can lead to rushed clinical trials and approvals based on uncertain evidence [2] Treatment & Dosage - Lower dosages can result in less revenue for pharmaceutical companies [2] - A second line of treatment may not always be beneficial for patients [2] Patient Needs & Conflicts - Clinicians and researchers should focus on patient needs, which can sometimes conflict with other factors [3]